This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 25/8/1635    most recent 01.ATV.0000171992.36710.1ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trion, A. Articles by Emeis, J.J. Search for Related Content PubMed PubMed Citation Articles by Trion, A. Articles by Emeis, J.J. Related Collections Animal models of human disease Pathophysiology Genetically altered mice

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1635.)
© 2005 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice

A. Trion; M.P.M. de Maat; J.W. Jukema; A. van der Laarse; M.C. Maas; E.H. Offerman; L.M. Havekes; A.J. Szalai; H.M.G. Princen; J.J. Emeis

From the Department of Cardiology (A.T., J.W.J., A.v.d.L.), Leiden University Medical Center, the Netherlands; Biomedical Research (A.T., M.P.M.d.M., M.C.M., E.H.O., L.M.H., H.M.G.P., J.J.E.), TNO, Leiden, the Netherlands; the Department of Hematology (M.P.M.d.M.), Erasmus Medical Center, Rotterdam, the Netherlands; and the Department of Medicine (A.J.S.), University of Alabama at Birmingham.

Correspondence to J.J. Emeis, Biomedical Research, TNO, Gaubius Bldg PO Box 2215, 2301 CE Leiden, The Netherlands. E-mail jj.emeis{at}pg.tno.nl

Objective— C-reactive protein (CRP) has been associated with risk of cardiovascular disease. It is not clear whether CRP is causally involved in the development of atherosclerosis. Mouse CRP is not expressed at high levels under normal conditions and increases in concentration only several-fold during an acute phase response. Because the dynamic range of human CRP is much larger, apolipoprotein E*3-Leiden (E3L) transgenic mice carrying the human CRP gene offer a unique model to study the role(s) of CRP in atherosclerosis development.

Methods and Results— Atherosclerosis development was studied in 15 male and 15 female E3L/CRP mice; E3L transgenic littermates were used as controls. The mice were fed a hypercholesterolemic diet to induce atherosclerosis development. Cholesterol exposure did not differ between E3L/CRP and E3L mice. Plasma CRP levels were on average 10.2±6.5 mg/L in male E3L/CRP mice, 0.2±0.1 mg/L in female E3L/CRP mice, and undetectable in E3L mice. Quantification of atherosclerosis showed that lesion area in E3L/CRP mice was not different from that in E3L mice.

Conclusion— This study demonstrates that mildly elevated levels of CRP in plasma do not contribute to the development of early atherosclerosis in hypercholesterolemic E3L/CRP mice.

C-reactive protein (CRP) is associated with incidence and severity of cardiovascular disease (CVD). Whether CRP is causally involved in atherosclerosis, the underlying cause of CVD, is unclear. This study in apolipoprotein E*3-Leiden transgenic mice demonstrated that mildly elevated levels of CRP in plasma did not contribute to atherosclerosis development.

Key Words: atherosclerosis • C-reactive protein • inflammation • mouse • transgene

This article has been cited by other articles:

				P. Welsh, P.H. Whincup, O. Papacosta, S.G. Wannamethee, L. Lennon, A. Thomson, A. Rumley, and G.D.O. Lowe Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men QJM, October 1, 2008; 101(10): 785 - 791. [Abstract] [Full Text] [PDF]

				T. B. Grammer, W. Marz, W. Renner, B. O. Bohm, and M. M. Hoffmann C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study Eur. Heart J., May 21, 2008; (2008) ehn191v1. [Abstract] [Full Text] [PDF]

				J. Wu, M. J. Stevenson, J. M. Brown, E. A. Grunz, T. L. Strawn, and W. P. Fay C-Reactive Protein Enhances Tissue Factor Expression by Vascular Smooth Muscle Cells: Mechanisms and In Vivo Significance Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 698 - 704. [Abstract] [Full Text] [PDF]

				S. K. Singh, M. V. Suresh, D. C. Prayther, J. P. Moorman, A. E. Rusinol, and A. Agrawal C-Reactive Protein-Bound Enzymatically Modified Low-Density Lipoprotein Does Not Transform Macrophages into Foam Cells J. Immunol., March 15, 2008; 180(6): 4316 - 4322. [Abstract] [Full Text] [PDF]

				D. Xing, F. G. Hage, Y.-F. Chen, M. A. McCrory, W. Feng, G. A. Skibinski, E. Majid-Hassan, S. Oparil, and A. J. Szalai Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc{gamma}RI)-Dependent Am. J. Pathol., January 1, 2008; 172(1): 22 - 30. [Abstract] [Full Text] [PDF]

				A. Kovacs, P. Tornvall, R. Nilsson, J. Tegner, A. Hamsten, and J. Bjorkegren Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia PNAS, August 21, 2007; 104(34): 13768 - 13773. [Abstract] [Full Text] [PDF]

				R. J. Bisoendial, J. J. P. Kastelein, S. L. M. Peters, J. H. M. Levels, R. Birjmohun, J. I. Rotmans, D. Hartman, J. C. M. Meijers, M. Levi, and E. S. G. Stroes Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects J. Lipid Res., April 1, 2007; 48(4): 952 - 960. [Abstract] [Full Text] [PDF]

				Y. Zhong, S.-H. Li, S.-M. Liu, P. E. Szmitko, X.-Q. He, P. W.M. Fedak, and S. Verma C-Reactive Protein Upregulates Receptor for Advanced Glycation End Products Expression in Human Endothelial Cells Hypertension, September 1, 2006; 48(3): 504 - 511. [Abstract] [Full Text] [PDF]

				J. P Casas, T. Shah, J. Cooper, E. Hawe, A. D McMahon, D. Gaffney, C. J Packard, D. S O'Reilly, I. Juhan-Vague, J. S Yudkin, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization Int. J. Epidemiol., August 1, 2006; 35(4): 922 - 931. [Abstract] [Full Text] [PDF]

				B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, I. Jialal, B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, and I. Jialal The Verdict Is Still Out Circulation, May 2, 2006; 113(17): 2128 - 2151. [Full Text] [PDF]

				M. V. Suresh, S. K. Singh, D. A. Ferguson Jr., and A. Agrawal Role of the Property of C-Reactive Protein to Activate the Classical Pathway of Complement in Protecting Mice from Pneumococcal Infection J. Immunol., April 1, 2006; 176(7): 4369 - 4374. [Abstract] [Full Text] [PDF]

				R. Bisoendial, R. Birjmohun, T. Keller, S. van Leuven, H. Levels, M. Levi, J. Kastelein, and E. Stroes Circ. Res., December 9, 2005; 97(12): e115 - e116. [Full Text] [PDF]

				J. Torzewski C-Reactive Protein and Atherogenesis: New Insights from Established Animal Models Am. J. Pathol., October 1, 2005; 167(4): 923 - 925. [Full Text] [PDF]

				H. Sun, T. Koike, T. Ichikawa, K. Hatakeyama, M. Shiomi, B. Zhang, S. Kitajima, M. Morimoto, T. Watanabe, Y. Asada, et al. C-Reactive Protein in Atherosclerotic Lesions: Its Origin and Pathophysiological Significance Am. J. Pathol., October 1, 2005; 167(4): 1139 - 1148. [Abstract] [Full Text] [PDF]

				U. Singh, S. Devaraj, and I. Jialal C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial Cells: Evidence that C-Reactive Protein Is a Procoagulant Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2216 - 2221. [Abstract] [Full Text] [PDF]

				E. T.H. Yeh A New Perspective on the Biology of C-Reactive Protein Circ. Res., September 30, 2005; 97(7): 609 - 611. [Full Text] [PDF]

				J. Nilsson CRP--Marker or Maker of Cardiovascular Disease? Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1527 - 1528. [Full Text] [PDF]